On the use of list prices in drug pricing research

14 March 2019 - In the limitations section of this article, we discussed in detail that list prices do not capture ...

Read more →

PBAC Public Summary Documents - November 2018 meeting (rejections and deferrals)

15 March 2019 - The Public Summary Documents (first time rejections and deferrals) from the November 2018 PBAC meeting are now ...

Read more →

Health Canada begins release of clinical data on drugs and devices

14 March 2019 - Health Canada launched two public databases on Wednesday as the first step in making clinical information ...

Read more →

CMS updates drug dashboards with prescription drug pricing and spending data

14 March 2019 - Dashboards further the agency’s efforts to increase price transparency throughout the healthcare system and create incentives ...

Read more →

Institute for Clinical and Economic Review publishes white paper on alternative models for pharmaceutical rebates

12 March 2019 - Paper explores how reforming or eliminating rebates may affect drug pricing, patient access, and incentives for future ...

Read more →

Direct-acting anti-virals for hepatitis C - outcome statement

8 March 2019 - The outcome statement for the direct-acting anti-virals for hepatitis C stakeholder meeting held on 13 December 2018 ...

Read more →

PBAC public summary documents - November 2018 meeting

1 March 2019 - The public summary documents (positive recommendations and subsequent decisions not to recommend) from the November 2018 PBAC ...

Read more →

EMA publishes agenda for 25-28 February 2019 CHMP meeting

25 February 2019 - The EMA has published a draft agenda for this week's CHMP meeting. ...

Read more →

FDA advances new efforts to promote development of safe and effective regenerative medicine products

15 February 2019 - Today, the FDA finalised two guidance documents regarding regenerative medicine therapies.  ...

Read more →

OIA responses: exploring ways to publish them

14 February 2019 - To support New Zealand's commitment to open government, PHARMAC is exploring ways to publish more of ...

Read more →

J&J becomes first drug maker to add prices to television ads

8 February 2019 - Johnson & Johnson said on Thursday it will start adding the price of its medicines to ...

Read more →

Identifying the need for good practices in health technology assessment-summary of the ISPOR HTA Council Working Group Report on Good Practices in HTA

26 January 2019 - The systematic use of evidence to inform healthcare decisions, particularly health technology assessment, has gained increased recognition.  ...

Read more →

2019 April price disclosure cycle – indicative prices

18 January 2019 - Indicative 1 April 2019 prices resulting from the 2019 April cycle of price disclosure have now been ...

Read more →

FDA is urged to mandate disclosure of clinical trial summaries as pilot program stalls

16 January 2019 - One year after the FDA launched a voluntary pilot program to release clinical study reports, which ...

Read more →

Revised guideline aims to strengthen global approach to development of new antibacterial medicines

14 January 2019 - EMA has published a PDF revision of its guideline on the evaluation of human medicines ...

Read more →